- Sony Biotechnology
- Sony Biotechnology
In their quest for answers, Dr. Moshe Sade-Feldman’s team at the Translational Cancer Immunology (TCI) laboratory at Massachusetts General Hospital (MGH), analyzes real-life data from patients treated with immunotherapies. Learn how the team used single-cell profiling to probe the role played by immune cells in patient tumors in the development of the response to cancer therapy.
Dr. Chris Emig, Founder and Chief Executive of Augmenta Bioworks The B-cell receptor repertoire can now be queried by next generation sequencing (NGS) at a scale that enables the rapid collection of millions of antibody sequences from any given individual. The resulting pool of rationally selected antibodies gives researchers access to a comprehensive database of antigen-specific binders and increases the chances of identifying the best antibody sequences. The growing volume of such NGS antibody repositories opens opportunities for alternative methods of therapeutic antibody discovery. Augmenta Bioworks, a biotechnology company headed by Chris Emig, PhD, Co-Founder and Chief Executive Officer, is actively engaged in the discovery of new therapeutics by harnessing the most powerful force in the fight against disease—natural human immunity. This group has developed a novel strategy called the DeepGrid™ platform, which combines single-cell sorting with RNA sequencing to pinpoint the protective immune response of individuals and translate these discoveries into therapies. Dr. Emig explains, "We’re currently working on immune profiling and antibody discovery. Augmenta provides deep insights into human immune repertoires and a technical suite for discovering antibodies of high therapeutic potential. We work with a range of scientists, from academics seeking better insights into human immunity...
As the global prevalence of allergic inflammation continues to rise, efforts towards discovery of novel therapeutic modalities are very significant. Canadian immunologist Dr. MacNeil and his team pursue this using flow cytometry to identify the mechanism of allergy induced inflammation. Using the Sony SH800 cell sorter, Dr. MacNeil's lab sorts hematopoetic stem cells for immune profiling of the activated mast cell population. Individual cells from this population are sorted into a 96-well plate— for studying genetic and epigenetic basis of allergic response.
Single-cell sequencing has proven invaluable to understanding the biology of heterogeneous samples such as brain or tumor tissues. However, sorting individual cells into wells for downstream sequencing does not provide adequate throughput needed for meaningful analysis of the epigenetic states of the cells. To address this challenge, this research team developed a new methodology to analyze properties of single cells by labeling cell nuclei with DNA "barcodes" and distributing them using the SH800 sorter from Sony Biotechnology.
Can antibodies be used as potential complements to vaccines? This team scours the planet looking for human donors to isolate PBMCs from those exposed to Rift Valley Fever in Kenya, to Ebola survivors. Supporting this important work, the Sony SH800 cell sorter has become an essential tool to isolate the right cells for a pipeline to generate antibody sequences that will ultimately build effective medical countermeasures.
David Savage's laboratory uses progressive cell sorting of large libraries to allosterically engineer protein biosensors and direct the genome editing activity of Cas9. Second in a series of real-world applications for the Sony SH800 cell sorter.
Learn how a developmental cell biology lab combined single-cell sorting with RNA sequencing to accelerate stem cell maturation and model cardiac abnormalities. This is the first in our profile series of real-world applications for the Sony SH800 cell sorter.